CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
Poziotinibdrug
Likely dose
Poziotinib 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02659514
NCT02659514Phase 2Completed
CompareCT.gov

A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

Spectrum Pharmaceuticals, Inc·interventional·Posted Jan 20, 2016·Updated Mar 11, 2022

In Brief

A Phase 2 clinical trial evaluating Poziotinib for Breast Cancer. Completed, enrolled 67 participants across 35 sites.

Detailed Summary

The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 20, 2016
Enrollment StartFeb 22, 2016
Primary CompletionMar 11, 2020
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 10.5 years ago

Interventions

Poziotinibdrug

8 mg oral tablets, administered QD.